- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07606846
Exteriorization Versus In Situ Hysterotomy Repair During Cesarean: Effects on Uterine Tone
22 maj 2026 uppdaterad av: Hannah Marie Kyllo, Stanford University
Uterine Exteriorization Versus In Situ Hysterectomy Repair During Cesarean Delivery: A Pilot Randomized Controlled Trial
During standard cesarean deliveries, there are two ways that obstetricians repair the incision on the uterus (hysterotomy after delivery of the baby.
One method involves lifting the uterus out of its regular place in the abdomen to repair the incision (uterine exteriorization for repair).
The second method involves leaving the uterus inside the abdomen to repair the uterus (in situ repair).
Both of these methods are regularly used by obstetricians during cesarean deliveries, and it is not currently known if one has benefits over the other.
Currently, surgeons use both methods, but lifting the uterus out of its place is slightly more common.
In this study, participants will be randomly assigned to have one of these techniques performed during their surgery.
Researchers will be investigating whether one technique or the other leads to better contraction of the uterus after delivery, less bleeding, less intra-operative nausea/vomiting, or a better patient experience than another.
Studieöversikt
Status
Har inte rekryterat ännu
Intervention / Behandling
Detaljerad beskrivning
There are two methods of uterine incision (hysterotomy) repair that can be utilized intra-operatively during a cesarean section: repair of the uterus within the abdomen (in situ) or temporary exteriorization of the uterus from the abdomen to repair the hysterotomy.
These two techniques have been previously compared in the literature, with outcomes that focus on intraoperative nausea/vomiting or blood loss measured as estimated blood loss or changes in hemoglobin.
Postpartum hemorrhage is the leading source of maternal morbidity and mortality worldwide.
Uterine atony, defined as inadequate uterine contraction to compress bleeding from the placental bed after delivery, is the leading cause of postpartum hemorrhage worldwide, accounting for upwards of 70% of cases.
Early assessments of and communication about uterine tone intra-operatively during cesarean deliveries are important for predicting and managing hemorrhage.
In a recent 2021 study, an 11-point (0 to 10) numeric rating scale for uterine tone, was shown to have strong interrater reliability and has since been implemented to assess uterine tone intra-operatively during cesarean sections at a number of institutions.
Low uterine tone scores have been found to be tightly correlated with postpartum hemorrhage and need for blood transfusion during hospitalization.
Uterine repair techniques have not yet been compared with regard to their impact on uterine tone intra-operatively, and this comparison may provide valuable information on how to optimize uterine tone through surgical technique, thereby decreasing the risk of hemorrhage and need for additional interventions.
The investigators propose a pilot randomized controlled trial comparing uterine exteriorization for hysterotomy repair versus in situ repair during cesarean sections.
The primary outcomes related to feasibility and acceptability will include: percent of patients approached who consented, percent of patients consented who obstetricians agreed to allow for randomization, and percent crossover from randomization arm.
The primary efficacy-related outcome will be uterine tone, as reported by the surgeon intra-operatively at multiple time points following delivery of the infant.
Secondary outcomes will include qualitative blood loss and use of medications to treat low uterine tone, intraoperative breakthrough pain, and nausea.
Studietyp
Interventionell
Inskrivning (Beräknad)
60
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Hannah Kyllo M. Resident Physician, MD
- Telefonnummer: 650-723-5403
- E-post: hkyllo@stanford.edu
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Age 18-55
- Undergoing cesarean section
Exclusion Criteria:
- Patient age <18 or >55
- Case urgency deemed too great for consent
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Uterine Exteriorization
For participants randomized to the control group (uterine exteriorization for repair), standard technique for cesarean delivery will be performed intra-operatively.
At the time of hysterotomy repair, the uterus will be exteriorized from the abdomen and will be sutured closed in typical fashion.
Following closure of the hysterotomy, the uterus will be returned to the abdomen.
The remainder of the surgery will be performed with standard technique.
|
The uterus will be temporarily exteriorized from the abdomen for repair of the hysterotomy (uterine incision) after delivery of the infant in a cesarean section.
|
|
Experimentell: In Situ Repair
For participants randomized to the experimental group (in situ repair), standard technique for cesarean delivery will be performed intra-operatively.
At the time of hysterotomy repair, the uterus will be left in situ and will be sutured closed in typical fashion.
The remainder of the surgery will be performed with standard technique.
|
Repair of the hysterotomy (uterine incision) within the abdomen (in situ) after delivery of the infant during a cesarean section.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Compliance/Feasibility
Tidsram: Duration of the study, approximately 2 years
|
Percentage of consented cesarean participants who were successfully treated as randomly allocated in each arm
|
Duration of the study, approximately 2 years
|
|
Efficacy Signal
Tidsram: Duration of the study, approximately 2 years
|
Mean quantitative blood loss, analyzed after log transformation in a regression model that adjusts for cesarean group (scheduled, 1st stage, and 2nd stage)
|
Duration of the study, approximately 2 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Feasibility: Enrollment
Tidsram: Duration of the study, approximately 2 years
|
Number of consented participants who underwent cesarean section and Obstetrician agreed to randomization at huddle
|
Duration of the study, approximately 2 years
|
|
Incidence of Intraoperative Breakthrough Pain between groups
Tidsram: Duration of the study, approximately 2 years
|
Duration of the study, approximately 2 years
|
|
|
Incidence of Intraoperative Vomiting between groups
Tidsram: Duration of the study, approximately 2 years
|
Duration of the study, approximately 2 years
|
|
|
Total operative time between groups
Tidsram: Duration of the study, approximately 2 years
|
Measured in minutes from skin incision to closure
|
Duration of the study, approximately 2 years
|
|
Time from fetal delivery to hysterotomy closure between groups
Tidsram: Duration of the study, approximately 2 years
|
In minutes
|
Duration of the study, approximately 2 years
|
|
10 Minute Uterine Tone Score between groups
Tidsram: Duration of the study, approximately 2 years
|
Uterine tone score 10 minutes after delivery of the placenta between groups, measured on a scale of 0 to 10, with "0" representing "no tone" and "10" representing excellent tone.
|
Duration of the study, approximately 2 years
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Studierektor: Jess Ansari, MD, MS, Stanford University
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
1 juni 2026
Primärt slutförande (Beräknad)
1 juni 2029
Avslutad studie (Beräknad)
1 juni 2029
Studieregistreringsdatum
Först inskickad
19 maj 2026
Först inskickad som uppfyllde QC-kriterierna
19 maj 2026
Första postat (Faktisk)
26 maj 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
27 maj 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
22 maj 2026
Senast verifierad
1 april 2026
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Patologiska processer
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Obstetriska förlossningskomplikationer
- Graviditetskomplikationer
- Blödning
- Puerperala störningar
- Livmoderblödning
- Dystoci
- Patologiska tillstånd, tecken och symtom
- Postpartum blödning
- Uterin tröghet
Andra studie-ID-nummer
- 84585
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
IPD-planbeskrivning
No patient level data is anticipated to be shared with other researchers for future use after this study.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .